Aggregate Market Opportunity† 2002

$6B

$6B

$2.5B

$1.5B

Total = $16B

Disclosed Clinical Pipeline

†Based on current annual sales of injectable heparins, rhGH and the combined sales  of oral and injectable products in diabetes. Osteoporosis sales include all oral agents.

SOURCE: Based on individual sales data from respective companies’ most recent annual reports

Previous slide

Next slide

Back to first slide

View graphic version